Nephro Care share price & results
- Jun 2026
- Jun 2026
Eastern-India nephrology-focused healthcare group running a 100-bed multispecialty hospital and a clinic network offering dialysis, kidney transplants, diagnostics and telemedicine.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 29.2 | +68.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.4 | +8.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. | ||
| Free cash flow margin | -6.18 | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. | |
| Revenue growth (YoY) | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. |
Price
Performance −41.6% 1Y
1Y: ₹139 on 24 Oct 2025 → ₹81.15. High ₹151 (18 Nov 2025), low ₹51.75 (30 Mar 2026).
- Previous close
- ₹79.8
- Market cap
- ₹143 Cr
- 52-week range
- ₹51.75 – ₹151
- One year
- −41.28%
- Price to earnings (FY ending Mar 2026)
- 51.07×
- Return on equity (FY ending Mar 2026)
- 4.92%
Overview
- Symbol
- NSE:NEPHROCARE
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Nephro Care does
Based on the company's own presentations, annual report and earnings calls.
Nephro Care India, founded in 2014 by Dr. Pratim Sengupta in Kolkata, specialises exclusively in kidney-related healthcare, delivered through an integrated hub-and-spoke network of clinics plus its flagship Vivacity Multispecialty Hospital in Madhyamgram, Kolkata. It earns from outpatient (OPD) consultations and treatment, inpatient (IPD) hospital care, and sale of medicines through its own pharmacy. The company has since added cardiology, medical oncology, gastroenterology, gynaecology and a dedicated Cardiothoracic & Vascular Surgery (CTVS) unit, and has government permission to begin kidney transplant operations at Vivacity Hospital.
Segments
- OPD Services
- IPD Services
- Pharmacy / Sale of Medicine
- Beds at flagship hospital (Vivacity, Madhyamgram)
- 100, incl. a 30-bed Critical Care Unit (ICU/HDU/RTU/NICU)
- Clinics
- 5+ (hub-and-spoke network across West Bengal)
- Team size
- 300+
- Dedicated dialysis centre capacity
- 24 beds (at Vivacity)
- Operation theatres
- 5 modular OTs + 1 minor OT (Vivacity)
- OPDs at Vivacity
- 10
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 1 fiscal year held (Mar 2026 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +348% (quarter to jun 2026 against jun 2025).
| Line item | Mar 2024 | Sept 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 18 | 28 | 17 | 39 | 23 | 27 | 29 |
| Expenses | 11 | 15 | 26 | 17 | 35 | 21 | 25 | 26 |
| Operating profit | 3 | 3 | 3 | 1 | 4 | 2 | 2 | 4 |
| Operating margin | 19.3% | 17.2% | 10.0% | 3.5% | 11.2% | 8.4% | 7.5% | 12.4% |
| Other income | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Depreciation | 1 | 0 | 2 | 1 | 2 | 1 | 2 | 1 |
| Profit before tax | 2 | 3 | 2 | -1 | 3 | 1 | 1 | 3 |
| Tax rate | 69.3% | 27.3% | 20.2% | 0.0% | 29.9% | 25.0% | 23.1% | 38.2% |
| Net profit | 1 | 2 | 1 | -1 | 2 | 0 | 1 | 2 |
| EPS (₹ per share) | 0.64 | 1.33 | 0.88 | -0.39 | 1.18 | 0.25 | 0.61 | 0.98 |
| Line item | Mar 2026 |
|---|---|
| Sales | 106 |
| Expenses | 97 |
| Operating profit | 9 |
| Other income | 2 |
| Interest | 0 |
| Depreciation | 6 |
| Profit before tax | 4 |
| Net profit | 3 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 12 | 16 | 16 | 16 |
| Reserves | 0 | 2 | 3 | 37 | 39 | 40 |
| Borrowings | 3 | 2 | 0 | 0 | 0 | 0 |
| Other liabilities | 2 | 3 | 6 | 15 | 11 | 16 |
| Total liabilities | 5 | 8 | 21 | 68 | 67 | 73 |
| Fixed assets | 1 | 3 | 5 | 31 | 34 | 34 |
| Capital work in progress | 2 | 0 | 1 | 1 | 1 | 1 |
| Investments | 0 | 2 | 7 | 19 | 14 | 12 |
| Other assets | 1 | 3 | 9 | 18 | 18 | 26 |
| Total assets | 5 | 8 | 21 | 68 | 67 | 73 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 0 | 1 | 4 | 1 | 7 | 2 |
| Cash from investing | -0 | -3 | -2 | -8 | -40 | -0 |
| Cash from financing | 0 | 2 | -0 | 6 | 36 | 0 |
| Net cash flow | 0 | 0 | 2 | -1 | 3 | 2 |
| Free cash flow | 0 | -2 | 4 | -2 | -23 | -6 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 0 | 20 | 1 | 2 | 26 | 25 |
| Inventory days | 9 | 42 | 35 | 14 | 34 | 32 |
| Days payable | 94 | 113 | 69 | 75 | 107 | 93 |
| Cash conversion cycle | -85 | -51 | -33 | -59 | -47 | -36 |
| Working capital days | -88 | -125 | -57 | -37 | -51 | -4 |
| Return on capital employed | 25.2% | 1.6% | 65.8% | 60.4% | 11.3% | 7.9% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
Income from IPD Services contributes 53.2% of reported segment revenue.
Quarter ended 30 Jun 2026 · Standalone
- Income from IPD Services 53.2%
₹15.65 crore
- Income from OPD Services 25.8%
₹7.58 crore
- Income from sale of medicines from pharmacy 20.2%
₹5.95 crore
- Add: Others 0.4%
₹0.12 crore
- Add: Interest Income 0.2%
₹0.05 crore
- Add: Profit on Sale of Investment 0.1%
₹0.04 crore
- Add: Dialysis machine Rental charges <0.1%
₹0.01 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| Income from IPD Services | 15.65 | 53.2% |
| Income from OPD Services | 7.58 | 25.8% |
| Income from sale of medicines from pharmacy | 5.95 | 20.2% |
| Add: Others | 0.12 | 0.4% |
| Add: Interest Income | 0.05 | 0.2% |
| Add: Profit on Sale of Investment | 0.04 | 0.1% |
| Add: Dialysis machine Rental charges | 0.01 | <0.1% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹29.41 crore
- Intersegment adjustment
- ₹3.29 crore
- Net segment revenue
- ₹26.11 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
Ownership
Who owns it
Promoters hold 61.71% as of Jun 2026; institutions added 0.22 pts since Mar 2026.
- Promoters 61.71%
- Foreign institutions 0.96%
- Domestic institutions 1.29%
- Public 36.03%
Who is on the register
Named in the Jun 2026 filing
Every holder of Nephro Care above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 60.98% | unchanged | |
| 0.29% | unchanged | |
| 0.29% | unchanged | |
| 0.15% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Nephro Care
Free account: one company. Everything above stays public.
Write why you follow Nephro Care and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Nephro Care
Guides on how to read this kind of business and the numbers that matter.